【直播】BioVerse 17-Recap of JPM25-Major News, Trends, and Sentiment

Why Attend this Event?

Event details

Speakers intro

Fay Xing is a partner at Panacea Venture, a fund that invests in life science companies globally.  She has had extensive experience in company formation and early-stage investments in biotech and medtech. She was previously partner at WuXi Healthcare Ventures (later 6 Dimensions Capital), CBC and Decheng Capital. She has a MD from Stanford Medical School and MBA from Harvard.

Biren Amin is a Managing Director, Biotechnology at Piper Sandler since March 2024. Prior to joining Piper Sandler, he served as the chief financial officer and chief strategy officer at Pyramid Biosciences, a private biotechnology company, where he was responsible for investor relations, capital raising and leading business development activities including monitoring key competitors for therapeutics targeting solid tumors and was responsible for in-licensing a TROP-2 ADC from GeneQuantum (Suzhou). Before Pyramid Biosciences, Biren served as the chief financial officer at Immuneering Corporation, a public clinical-stage oncology company. He previously spent 10 years at Jefferies Financial Group Inc. covering small and mid-cap biotechnology companies focused on oncology, central nervous system disorders, ophthalmology and rare diseases and was II ranked from 2017-2020. Prior to Jefferies Financial Group Inc., Biren spent several years in equity research and within a business development team at Aventis Pharma (now, part of Sanofi).

Biren graduated from University of the Sciences with a bachelor’s degree in pharmacy and his Master of Business Administration degree from the Leonard Stern School of Business at New York University.

Dr. Sun, serving as the Chief Business Officer (CBO), currently leads Global Business Development and Alliance Management at Hansoh Pharmaceutical Group. Over the past three years, he and his team have accomplished over 20 licensing and collaboration deals, including two licensing agreements with GSK on ADCs and recently one small molecule GLP-1 out-licensing to Merck (MSD). Dr. Sun also plays a pivotal role in supporting Hansoh R&D by evaluating and accessing new technologies, platforms, and modalities.

Prior to joining Hansoh, Dr. Sun dedicated 19 years to Daiichi Sankyo, where he spent the initial five years in R&D, contributing to activities ranging from target discovery to clinical development. Transitioning to the Business Development division, he successfully identified, evaluated, and negotiated numerous partnership opportunities.

Dr. Sun holds an MD from Peking University Medical School, as well as master’s and doctoral degrees in Cell Biochemistry from the University of Tokyo. Additionally, he earned an MBA from Columbia Business School.

Naveen Krishnan is the Managing Director of Mirae Asset Capital Life Science with nearly 20 years of experience in healthcare spanning biomedical research, clinical/medical training, biotech operating experience, and venture capital investing. Prior to leading Mirae Asset Capital Life Science, he helped lead healthcare investments for Bayer as part of its venture arm, Leaps by Bayer. In this role he sat on the board of seven companies and led or supported over 20 deals over the past few years including companies that underwent exit, developed partnerships with big pharma, or became profitable. Prior to Bayer he helped build biotech companies in cell and gene therapy (Aspen Neuroscience) and regenerative medicine including leading operations, business and corporate development, clinical trials, and clinical operations for public and private companies. Before building biotech companies, Dr. Krishnan was a surgical resident based out of Georgetown University Hospital in Washington, D.C.

Naveen received his Bachelor’s degree in Brain and Cognitive Sciences from MIT, a Master’s degree in Public Health from the University of Cambridge (Gates Cambridge Scholar), and his medical degree from Dartmouth (Albert Schweitzer Fellow).

Leon ‘Jun’ Tang, is the founding partner of InScienceWeTrust BioAdvisory, a business development company focused on the East-West cross-border partnerships in the pharmaceutical industry. Dr. Tang is also the founder of InScienceWeTrust Community, which has more than 2,000+ members from Asian biotech community. He is also the c-founder and host of Bioverse webinar.

Dr. Tang serves as a scientific advisor to Mianus Capital, a boutique US-based healthcare PE/VC fund currently focused on ophthalmology. He is also an advisor to BioSpark, an Asian biotech professional’s association based in Massachusetts.

Previously, Dr. Tang was a senior director of BD Search & Evaluation at Shanghai Henlius Biotech, a public biotech listed on Hong Kong Stock Exchange, a biotech sell-side analyst at Barclays Investment Bank, and a senior manager/senior analyst at the philanthropic venture fund of Cancer Research Institute of New York.

Dr. Tang has published 50+ academic papers, some of which are in Nature Reviews Drug Discovery, Lancet Oncology, Science Translational Medicine, Nature Communications, Science Advances, PNAS, etc. Dr. Tang received his bachelor’s degree from Tianjin University, master’s degree from Nankai University, PhD from Icahn School of Medicine of Mount Sinai, and postdoctoral training at Memorial Sloan Kettering Cancer Center. 

Organizers

Sponsor

Partner &Collaborators